MMED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MiniMed Group Inc (MMED) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong international growth, a promising product pipeline, and recent positive catalysts such as the launch of its MiniMed Flex™ insulin pump. Despite a slight dip in price recently, the stock is attractively valued with multiple analysts maintaining Buy or Overweight ratings, and the long-term growth prospects appear favorable.
The MACD is positive at 0.125 and contracting, indicating a bullish trend. RSI is neutral at 58.081, and moving averages are converging, suggesting consolidation. Key support is at 14.2, and resistance is at 15.482. The stock shows a 70% chance of a slight decline (-0.17%) in the next day but a positive trend of 0.96% in the next week and 1.03% in the next month.
Launch of MiniMed Flex™, a smart insulin pump, in the U.S.
Strong international growth and a promising product pipeline.
Analysts highlight the company's favorable risk/reward profile and potential for long-term growth.
U.S. market softness as customers await the MiniMed Flex™.
Lowered price targets from some analysts due to broader medtech valuation concerns.
No financial data available for the latest quarter. However, analysts have noted strong international growth and a solid FY27 guide.
Analysts are largely positive, with multiple Buy or Overweight ratings. Price targets range from $20 to $67, with the majority in the $20-$26 range, indicating significant upside potential from the current price of $14.705.
